Gamida Cell
Gamida Cell Q2 FY23: net loss $31.7M
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-23-067082
- Document
- 10-Q
Key figures from this report
These are the numbers Gamida Cell reported for Q2 FY23, the quarter ended Jun 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Net income−$31.7MAgainst −$18.6M in Q2 FY2210-Q income statement, on EDGAR
- Cash and cash equivalents$54.1M+43% from $37.9M in Q2 FY2210-Q balance sheet, on EDGAR
- Cash from operations−$22.0MAgainst −$13.9M in Q2 FY2210-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
